BiotechTube

Perampanel Oral Tablet

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Epilepsy

Conditions

Epilepsy

Trial Timeline

Apr 18, 2018 → Dec 15, 2021

NCT ID
NCT03457129

About Perampanel Oral Tablet

Perampanel Oral Tablet is a approved stage product being developed by Eisai for Epilepsy. The current trial status is completed. This product is registered under clinical trial identifier NCT03457129. Target conditions include Epilepsy.

What happened to similar drugs?

20 of 20 similar drugs in Epilepsy were approved

Approved (20) Terminated (6) Active (0)
✅ZonegranEisaiApproved
✅Perampanel + PlaceboEisaiApproved
✅perampanelEisaiApproved
✅PerampanelEisaiApproved
✅zonisamide low dose group + zonisamide high dose groupEisaiApproved
✅Zonisamide at targeted daily doses of 100-500 mg/day + Placebo administered to match targeted daily doses of 100-500 mg/dayEisaiApproved
✅zonisamideEisaiApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03457129ApprovedCompleted

Competing Products

20 competing products in Epilepsy

See all competitors
ProductCompanyStageHype Score
perampanelEisaiPhase 2
35
LacosamideUCBPhase 3
40
Zonisamide + PlaceboEisaiPhase 3
32
ZonegranEisaiApproved
35
perampanel + perampanelEisaiPhase 1
29
Perampanel + PlaceboEisaiApproved
35
perampanelEisaiApproved
35
E2007 + PlaceboEisaiPhase 2
35
Placebo + RufinamideEisaiPhase 3
40
E2007 (perampanel) + PlaceboEisaiPhase 2
35
perampanelEisaiPhase 3
40
PerampanelEisaiPre-clinical
26
Zonisamide + CarbamazepineEisaiPhase 3
40
PerampanelEisaiApproved
43
Perampanel and Microgynon-30 + Perampanel and Microgynon-30EisaiPhase 1
29
PerampanelEisaiPhase 2
35
Zonisamide + PlaceboEisaiPhase 3
40
zonisamide low dose group + zonisamide high dose groupEisaiApproved
43
E2007 + E2007 + PlaceboEisaiPhase 2
35
Zonisamide at targeted daily doses of 100-500 mg/day + Placebo administered to match targeted daily doses of 100-500 mg/dayEisaiApproved
35